NEWS

Non-nelidone-an innovative drug for type 2 diabetic kidney disease

Release time:

2023-08-11 14:29

 

 

Diabetic kidney disease (DKD) is1Type and2The serious complications of type 2 diabetes have gradually become the end-stage renal disease (ESRD) is one of the major diseases that affect the health of our people. our country2Type diabetes (T2DM) caused by chronic kidney disease (CKD) Patient apex.3108Ten thousand, near40%of2Type 2 diabetes can develop chronic kidney disease. From the pathophysiological mechanism,2The development of chronic kidney disease in patients with type 2 diabetes is mainly driven by three factors, including hemodynamic factors, metabolic factors and inflammatory/Fibrosis factors. At present, the treatment of diabetic nephropathy focuses on improving hemodynamic and metabolic factors, and for the treatment of diabetic nephropathy by mineralocorticoid receptor (MR) Excessive activation of the important target of inflammation and fibrosis, there is still a lack of effective targeted treatment measures, and there is an urgent need for innovative drugs in clinical practice.

Non-nelidone (Finerenone) is the world's first approved for use in the treatment2Type 2 diabetic kidney disease (T2DKD)MRAinnovative drugs. As a novel non-steroidal selective mineralocorticoid receptor antagonist (MRA), nonneridone can directly inhibit the excessive activation of mineralocorticoid, antagonize inflammation and fibrosis, and effectively delay the progression of diabetic kidney disease.

traditionalMRA(SteroidsMRA), such as spironolactone and eplerenone, etc., are mainly used to treat hypertension and improve the prognosis of heart failure, but there are sex hormone-related adverse reactions (such as gynecomastia) or low binding efficacy with mineralocorticoid receptors. And new typeMRABecause of its high selectivity for mineralocorticoid receptor and low affinity for androgen, progesterone, estrogen and glucocorticoid receptor, felneridone has no sex hormone related adverse reactions and good safety.

In chronological order, non-nellione in the United States (2021Year7Month), EU (2022Year2Month), Japan (2022Year2month) and China (2022Year6month) has been approved for listing.

2023Year1Month, Tour®(Generic name: non-nelidone tablets) The strength of the latest national health insurance directory for treatment.2Type diabetes (T2D) adult patients with related chronic kidney disease.2023Year3Since January, it has been officially implemented. This will greatly improve the accessibility of non-nelidone and benefit more patients.

2023Year5In January, the domestic approved population of non-nellidone was further expanded2The early stages of type 2 diabetes-associated chronic kidney disease (with albuminuria) provide clinicians with new means of early disease intervention to maximize patient benefit. Furthermore, the inclusion of cardiovascular-related benefits (reduced risk of cardiovascular death and hospitalization for heart failure) in the indication for non-nexidone allows for both control of progression of renal disease in diabetic patients and cardiovascular risk in patients.

 

 

Quote:

https://www.rmzxb.com.cn/c/2023-07-17/3379149.shtml

https://new.qq.com/rain/a/20230303A07PLP00

https://new.qq.com/rain/a/20230105A04VNY00

http://endo.dxy.cn/article/856542